CSL CEO on Results, Global Business Outlook

Aug. 14 (Bloomberg) -- Paul Perreault, chief executive officer of CSL Ltd., the world’s second-biggest maker of blood-derived therapies, talks about the company's financial performance and business outlook. CSL, reported a 19 percent jump in annual profit, boosted by demand in the U.S. and Europe for Hizentra, an infection-fighting infusion. Perreault speaks with Susan Li on Bloomberg Television's "First Up." (Source: Bloomberg)

QuickTake: Shinzo Abe’s Shock Therapy
10:36 - On today’s "QuickTake" topic, Vonnie Quinn reports on Abenomics and attempts to stave off deflation in Japan. She speaks on "Bloomberg Markets: European Close.” (Source: Bloomberg)
  • Full Show: Surveillance (02/22)
  • WTO Director General Azevedo on Trade, Brexit, Trump
  • WTO’s Azevedo: Every Country Complains About Unfair Trade